Edward Machage Mgelea1, R Kisenge, S Aboud. 1. Department of Paediatrics and Child Health, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania. drmgelea@gmail.com.
Abstract
BACKGROUND: The performance of clinical and immunological criteria to predict virological failure in HIV-infected children receiving antiretroviral therapy (ART) is not well documented. OBJECTIVE: To determine the validity of clinical and immunological monitoring in detecting virological failure in children on ART. METHODS: A total of 218 children were included in the study. All were from care and treatment clinics in Dar es Salaam, Tanzania. Their mean age was 10.6 years, 122 (56.0%) were males, and the mean time on ART was 40.9 months. The study was conducted from August 2011 to March 2012. Data on sociodemographic and clinical characteristics and immunological and virological failure were based on World Health Organization definitions. Blood samples were collected for CD4+ T-cell count and viral load tests. RESULTS: Of 217 children with available viral load results, 124 (57.1%) had virological failure (>400 copies/mL), 25.0% immunological failure and 11.5% clinical failure. The sensitivity, specificity, positive predictive value and negative predictive value of clinical criteria were 12.9%, 90.3%, 64.0% and 43.8%, respectively, those for immunological criteria 22.6%, 73.1%, 53.3% and 41.4%, and those for the combination of clinical and immunological monitoring 25.8%, 69.9%, 53.3% and 41.4%. Children who received nevirapine (NVP)-based regimens were two times more likely (odds ratio 2.0; 95% confidence interval 1.20 - 3.64) to have virological failure than those on efavirenz and protease inhibitor-based regimens. CONCLUSIONS: The study demonstrated poor performance of currently recommended clinical and immunological criteria for monitoring HIV-infected children on ART. Moreover, children on NVP-based regimens had a higher risk of developing virological failure than those on other regimens.
BACKGROUND: The performance of clinical and immunological criteria to predict virological failure in HIV-infectedchildren receiving antiretroviral therapy (ART) is not well documented. OBJECTIVE: To determine the validity of clinical and immunological monitoring in detecting virological failure in children on ART. METHODS: A total of 218 children were included in the study. All were from care and treatment clinics in Dar es Salaam, Tanzania. Their mean age was 10.6 years, 122 (56.0%) were males, and the mean time on ART was 40.9 months. The study was conducted from August 2011 to March 2012. Data on sociodemographic and clinical characteristics and immunological and virological failure were based on World Health Organization definitions. Blood samples were collected for CD4+ T-cell count and viral load tests. RESULTS: Of 217 children with available viral load results, 124 (57.1%) had virological failure (>400 copies/mL), 25.0% immunological failure and 11.5% clinical failure. The sensitivity, specificity, positive predictive value and negative predictive value of clinical criteria were 12.9%, 90.3%, 64.0% and 43.8%, respectively, those for immunological criteria 22.6%, 73.1%, 53.3% and 41.4%, and those for the combination of clinical and immunological monitoring 25.8%, 69.9%, 53.3% and 41.4%. Children who received nevirapine (NVP)-based regimens were two times more likely (odds ratio 2.0; 95% confidence interval 1.20 - 3.64) to have virological failure than those on efavirenz and protease inhibitor-based regimens. CONCLUSIONS: The study demonstrated poor performance of currently recommended clinical and immunological criteria for monitoring HIV-infectedchildren on ART. Moreover, children on NVP-based regimens had a higher risk of developing virological failure than those on other regimens.
Authors: Adeodata Kekitiinwa; Alexander J Szubert; Moira Spyer; Richard Katuramu; Victor Musiime; Tawanda Mhute; Sabrina Bakeera-Kitaka; Oscar Senfuma; Ann Sarah Walker; Diana M Gibb Journal: Pediatr Infect Dis J Date: 2017-06 Impact factor: 2.129
Authors: Mark M Manak; Linda L Jagodzinski; Ashley Shutt; Jennifer A Malia; Mike Leos; Jason Ouellette; Siriwat Akapirat; Donn L Colby; Nittaya Phanuphak; Leigh Anne Eller; Merlin L Robb; Mark de Souza; Jintanat Ananworanich; Sheila A Peel Journal: J Clin Microbiol Date: 2019-09-24 Impact factor: 5.948
Authors: Adwoa K A Afrane; Bamenla Q Goka; Lorna Renner; Alfred E Yawson; Yakubu Alhassan; Seth N Owiafe; Seth Agyeman; Kwamena W C Sagoe; Awewura Kwara Journal: BMC Infect Dis Date: 2021-08-02 Impact factor: 3.090